ERBB3

Chr 12ARAD

erb-b2 receptor tyrosine kinase 3

Also known as: ErbB-3, FERLK, HER3, LCCS2, MDA-BF-1, VSCN1, c-erbB-3, c-erbB3

ERBB3 encodes a receptor tyrosine kinase that binds neuregulin-1 and forms heterodimers with other EGFR family members to activate cell proliferation and differentiation pathways. Mutations cause lethal congenital contracture syndrome, an autosomal recessive disorder characterized by severe arthrogryposis, hydrops fetalis, and intrauterine or neonatal death. The gene is not constrained against loss-of-function variants (pLI near zero), consistent with the recessive inheritance pattern observed in this severe early-onset condition.

GeneReviewsOMIMResearchSummary from RefSeq, UniProt
MultiplemechanismAR/ADLOEUF 0.693 OMIM phenotypes
Clinical SummaryERBB3
Population Constraint (gnomAD)
Low constraint (pLI 0.00) — loss-of-function variants are relatively tolerated in the population.
📋
ClinVar Variants
28 unique Pathogenic / Likely Pathogenic· 93 VUS of 257 total submissions
💊
Clinical Trials
8 active or recruiting trials — potential therapeutic options may be available
📖
GeneReview available — ERBB3
Authoritative clinical overview · Recommended first read
Open GeneReview ↗

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint
0.69LOEUF
pLI 0.000
Z-score 3.71
OE 0.52 (0.400.69)
Tolerant

Typical tolerance to LoF variation

Missense Constraint
1.39Z-score
OE missense 0.86 (0.800.91)
633 obs / 739.4 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios
LoF OE0.52 (0.400.69)
00.351.4
Missense OE0.86 (0.800.91)
00.61.4
Synonymous OE1.05
01.21.6
LoF obs/exp: 36 / 69.4Missense obs/exp: 633 / 739.4Syn Z: -0.61
Curated Mechanism (G2P)Gene2Phenotype (DDG2P) ↗
strongERBB3-related Hirschprung disease with intestinal pseudo-obstructionOTHERAR
strongERBB3-related lethal congenital contracture syndromeOTHERAR

Predictions shown for reference only — model trained on dominant genes, not applicable to AR conditions.

DN
0.76top 25%
GOF
0.83top 10%
LOF
0.2581th %ile

The Badonyi & Marsh prediction model was trained exclusively on dominant disease genes. Predictions are not reliable for genes with autosomal recessive inheritance and are shown at reduced opacity for reference only.

Literature Evidence

GOFERBB2 and ERBB3 somatic gain-of-function mutations, which may be targeted by anti-ERBB2 therapies, were reported by high-throughput sequencing studies in 1% and 2% of invasive breast cancers respectively.PMID:27602491

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312.

ClinVar Variant Classifications

257 submitted variants in ClinVar

Classification Summary

Pathogenic13
Likely Pathogenic15
VUS93
Likely Benign53
Benign37
Conflicting3
13
Pathogenic
15
Likely Pathogenic
93
VUS
53
Likely Benign
37
Benign
3
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
2
4
7
0
13
Likely Pathogenic
11
3
1
0
15
VUS
2
85
6
0
93
Likely Benign
1
10
18
24
53
Benign
0
5
28
4
37
Conflicting
3
Total161076028214

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

ERBB3 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

3D Protein StructureAlphaFold

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

Bladder CancerTriple Negative Breast CancerCastration-resistant Prostate Cancer

A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours

ACTIVE NOT RECRUITING
NCT05057013Phase PHASE1, PHASE2Cancer Research UKStarted 2021-11-10
HMBD-001HMBD-001 and enzalutamide
Breast Cancer

NeoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE Trial

ACTIVE NOT RECRUITING
NCT05569811Phase PHASE2SOLTI Breast Cancer Research GroupStarted 2022-11-25
Patritumab deruxtecanChemotherapyLetrozole
Advanced Malignant Solid NeoplasmEGFR Gene AmplificationEGFR Gene Mutation

Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation

ACTIVE NOT RECRUITING
NCT03065387Phase PHASE1M.D. Anderson Cancer CenterStarted 2017-10-31
EverolimusNeratinibPalbociclib
Non-Small Cell Lung CancerPancreatic CancerLocally Advanced Solid Tumor

Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation

ACTIVE NOT RECRUITING
NCT05919537Phase PHASE1Hummingbird BioscienceStarted 2023-09-06
HMBD-001DocetaxelNab-paclitaxel
Advanced Solid Tumor

A Clinical Study of SYS6023 in Patients With Advanced Solid Tumors

RECRUITING
NCT07110883Phase PHASE1CSPC Megalith Biopharmaceutical Co.,Ltd.Started 2024-08-15
SYS6023
HER2-positive Metastatic Breast CancerFirst-line Treatment

Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial

RECRUITING
NCT06278870Phase PHASE3Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityStarted 2023-09-06
disitamab vedotinPyrotinibtrastuzumab
Locally Advanced Lung Non-Small Cell CarcinomaMetastatic Lung Non-Small Cell CarcinomaStage III Lung Cancer AJCC v8

Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation

RECRUITING
NCT07012031Phase PHASE1, PHASE2National Cancer Institute (NCI)Started 2026-08-07
Biopsy ProcedureBiospecimen CollectionComputed Tomography
Solid Tumor, Adult

Patritumab Deruxtecan in Patients With Solid Tumor Harboring an NRG1 Fusion

RECRUITING
NCT06383884Phase PHASE2Samsung Medical CenterStarted 2024-08-13
Patritumab Deruxtecan
Clinical Literature
Open Research Assistant →